Delphia (USA)’s MacroGenics MGNX Stock Holding History

Delphia (USA)’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-37,988	Closed	-$203K	–	112
2023 Q2	$203K	Sell	37,988 -23,059	-38%	-$142K	0.32%	160
2023 Q1	$438K	Buy	+61,047	New	+$368K	0.54%	51

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Delphia (USA)'s MGNX Position: Q3 2023 in Review

Delphia (USA) sold out of MacroGenics (MGNX) in Q3 2023, closing a stake of 37,988 shares — an estimated $203K sold.

Delphia (USA) first reported a position in MGNX in Q1 2023 and held it in 2 quarters. The position peaked at $438K in Q1 2023. 127 funds tracked by Wall St. Rank hold MGNX as of Q3 2023.

Delphia (USA) reported no remaining MacroGenics position as of Q3 2023 after selling out during the quarter.
Delphia (USA) sold 37,988 MacroGenics shares in Q3 2023, an estimated $203K.
Delphia (USA) first reported a position in MacroGenics in Q1 2023 and held it in 2 quarters.
Delphia (USA)'s MacroGenics position peaked at $438K in Q1 2023.
127 funds tracked by Wall St. Rank held MacroGenics as of Q3 2023.

Based on Delphia (USA)'s 13F filing for Q3 2023, filed 15 Nov 2023.